Claim Missing Document
Check
Articles

Found 1 Documents
Search

Review: Drug Interactions Between Depression and Epilepsy Therapy Erwin Samsul; Sandrina Nur Yulianda; Rahmawati Eka Sari; Dina Nurfauziah Rahmi; Rahma Nur Afifah; Risma Nur Ramadhani; Annisa Azhalia Syakina; Selvina Nirmaya Saputri; Listra Febrina Taruk
Journal of Pharmaceuticals and Natural Sciences Vol. 3 No. 2 (2026): J Pharm Nat Sci
Publisher : B-CRETA Publisher (CV. Borneo Citra Kreatama)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70392/jpns.v3i2.48

Abstract

Background: Managing comorbid depression and epilepsy is challenging due to complex drug-drug interactions (DDIs). Objective: This systematic review evaluates clinically significant pharmacokinetic and pharmacodynamic interactions between antidepressants and antiepileptic drugs (AEDs). Methods: A systematic search was conducted across PubMed, ScienceDirect, and Google Scholar (2010–2025) following PRISMA guidelines. Results: Of 377 identified records, 24 studies met the inclusion criteria. Pharmacokinetic interactions (n=18; 75%) primarily involve the CYP450 enzyme system, notably CYP2D6 inhibition by fluoxetine and induction by carbamazepine. Significant pharmacodynamic risks include serotonin syndrome (n=3) and lowered seizure thresholds. Conclusion: While modern therapies offer better safety profiles, specific combinations like valproate-lamotrigine or SSRI-tramadol require rigorous monitoring. Clinical Implications: Pharmacists must prioritize screening for enzyme-inducing AEDs to prevent therapeutic failure or toxicity in neuropsychiatric care.